RTP Mobile Logo
Lung Cancer Update, Issue 2, 2012
Released October 2012

Featuring interviews with Drs D Ross Camidge, Bruce E Johnson, Panos Fidias and Luis Paz-Ares. (Text and Audio Content)

CE Disclosures and Faculty Information


    Lung cancer is the leading cause of cancer mortality in the United States for both men and women, resulting in more deaths than breast, prostate, colon and pancreatic cancer combined. Progress in the screening, prevention and treatment of this disease has been limited, and approximately 85% of patients who develop lung cancer will die of it. Traditional chemotherapy, surgery and radiation therapy have had a modest effect on long-term outcomes. However, the advent of biologic agents in lung cancer has led to recent improvements in disease-free and overall survival in select patient populations. Published results from ongoing and completed studies lead to the continual emergence of novel therapeutic strategies and changes in the indications for existing treatments. In order to offer optimal patient care — including the option of clinical trial participation — the practicing clinician must be well informed of these advances. Featuring information on the latest research developments along with expert perspectives, this CME program is designed to assist medical oncologists and radiation oncologists with the formulation of up-to-date clinical strategies for the care of patients with lung cancer.

    • Identify distinct subtypes of adenocarcinoma of the lung — including those with EGFR or K-ras mutations, EML4-ALK gene fusions, ROS1 rearrangements and other recently identified driver mutations — and the investigational and approved treatment options for patients expressing these biomarkers.
    • Describe emerging efficacy and tolerability data with irreversible EGFR tyrosine kinase inhibitor therapy for patients with advanced EGFR-mutant NSCLC and combined EGFR targeting in patients with acquired resistance to EGFR tyrosine kinase inhibitors.
    • Develop an evidence-based approach to the selection of induction and continuation maintenance biologic therapy and/or chemotherapy in patients with advanced NSCLC.
    • Describe the rationale for and emerging data with tumor immunotherapy directed at PD-1 in lung cancer and other solid tumors.
    • Recall the scientific rationale for ongoing investigation of novel agents or therapeutic approaches in lung cancer, and counsel appropriately selected patients about study participation.

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.


    Research To Practice designates this enduring material for a maximum of 3 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


    This CME activity contains both audio and print components. To receive credit, the participant should review the CME information, listen to the audio MP3s, read the text portion, complete the Post-test with a score of 70% or better and fill out the Educational Assessment and Credit Form located on our website at ResearchToPractice.com/LCU212/CME. The text portion of this activity contains edited comments, clinical trial schemas, graphics and references that supplement the audio MP3s, as well as links to relevant full-text articles, abstracts, trial information and other web resources.

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr CamidgeAdvisory Committee: ARIAD Pharmaceuticals Inc, Astellas, Boehringer Ingelheim Pharmaceuticals Inc, Chugai Pharmaceutical Co Ltd, Novartis Pharmaceuticals Corporation, Pfizer Inc. Dr JohnsonAdvisory Committee: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Chugai Pharmaceutical Co Ltd, Genentech BioOncology, Millennium: The Takeda Oncology Company, Pfizer Inc, Sanofi; Speakers Bureau: AstraZeneca Pharmaceuticals LP, Chugai Pharmaceutical Co Ltd, Genentech BioOncology. Dr FidiasAdvisory Committee: Genentech BioOncology. Dr Paz-AresConsulting Agreements: Bayer HealthCare Pharmaceuticals, Lilly USA LLC, Pfizer Inc, Roche Laboratories Inc; Paid Research: Boehringer Ingelheim Pharmaceuticals Inc.

    EDITORDr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Abbott Laboratories, Allos Therapeutics, Amgen Inc, ArQule Inc, Astellas, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Foundation Medicine Inc, Genentech BioOncology, Genomic Health Inc, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Incyte Corporation, Lilly USA LLC, Medivation Inc, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals Inc and Teva.
    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Astellas, Biodesix Inc, Celgene Corporation, Daiichi Sankyo Inc, Genentech BioOncology and Lilly USA LLC.

    Last review date: October 2012
    Expiration date: October 2013

    After completing the Post-test, learners may download and review the answers here in order to identify further areas of study.

Acknowledge and close

Listen to audio:
Lung Cancer Update, Issue 2, 2012
Released October 2012

Featuring interviews with Drs D Ross Camidge, Bruce E Johnson, Panos Fidias and Luis Paz-Ares. (Text and Audio Content)

Read print: